/
Login
Analysis Scores
Damodaran ?
53/100
Dalio Risk ?
57/100
Piotroski ?
6/9
Neutral
Operating cash flow data missing (C3, C4)
Graham ?
A$2.3
Pahalı
Active Metric?
4/4
Confidence?
72%
Valuation
Potential?
-1.1%
ROIC ?
10.0%
DCF Value ?
10.80
Debt Cycle?
Geç Genişleme
Data
Data ?
7329
1997-11-28 → 2026-08-31
Risk Analysis (VaR)
Düşük
252 days
Annual Volatility ?
%15.2
VaR 95% ?
%1.59
daily max loss
VaR 99% ?
%2.25
daily max loss
CVaR 95% ?
%2.24
expected loss (tail)
Max Drawdown ?
%17.5
19.05.2026 → 26.08.2026
Skewness ?
-0.05
Parametrik%1.59
Historik%1.45
Cornish-Fisher%1.58
Return Distribution
Fundamental & Technical Analysis
TRAMA-99 Trend — Downtrend
Price (4.67), TRAMA-99 line's %6.8 below. Downtrend ongoing — technical outlook negative. Pressure may continue until TRAMA is broken above.
Price:: 4.67
TRAMA: 5.0132
Difference: %-6.8
Profitability
Net Profit Margin
%9.6
Net profit margin %9.6 — positive but low. Compared to previous quarter +0.0 point increase.
ROE – Özkaynak Getirisi (TTM)
%7.8
ROE %7.8 — low return on equity.
EBITDA Margin
%37.8
EBITDA margin %37.8 — operationally very efficient.
Gross Profit Margin
%63.9
Gross profit per revenue %63.9. Strong pricing power.
Free Cash Flow Margin (TTM)
%15.2
TTM Free Cash Flow is %15.2'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio
23.9x
Sector: 13.5x
F/K 23.9x — sector median's (13.5x) %78 above. Expensive zone.
P/B Ratio
3.74x
Sector: 2.25x
PD/DD 3.74x — sector median's %66 above. Expensive book value.
EV/EBITDA
8.0x
Sector: 6.2x
EV/EBITDA 8.0x — sector median's (6.2x) %29 above. EBITDA’ya göre pahalı.
Indebtedness
Current Ratio
0.56x
Current ratio 0.56x — short-term liabilities exceed current assets. Liquidity risk.
Net Debt / EBITDA
2.1x
Net Borç/EBITDA 2.1x — manageable debt level.
Debt / Equity
1.29x
Borç/Özkaynak 1.29x — moderate financial leverage.
Interest Coverage
11.8x
Interest coverage 11.8x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY)
%+0.8
Revenue YoY %0.8 grew — positive but slow growth.
Net Profit Growth (YoY)
%+33.9
Net profit YoY %33.9 increased — strong profit growth.
Score Explanations
Lothien Robustness
56/100
Good robustness (56/100). The company shows a generally balanced financial profile; some areas have room for improvement.
Strong
Potential
-1.1%
Minus %1.1 expected value (4.62) vs current price comparison. 4/4 valuation models give 'BUY' signal. Model confidence %72.
Components: PE target: 2.69 | P/B target: 2.93 | EV/EBITDA target: 3.63 | DCF target: 10.80
Damodaran Valuation
53/100
Moderate Damodaran score (53/100). ROIC (%10.0) – WACC (%7.9) farkı +2.0 baz puan. Value creation capacity limited.
Moderate
Dalio Risk Analysis
57/100
Moderate debt risk (57/100). Interest coverage ratio 11.8x — strong. Borç/EBITDA 2.1x — manageable.
Leverage: 72/100 | Debt Service: 64/100 | Quality: 86/100
ROIC – Sermaye Getirisi
%10.0
ROIC (%10.0) slightly exceeds cost of capital (2.0 puan) aşıyor.
WACC: %7.9
DCF Discounted Cash Flow
10.80
DCF modeli 10.80 target value produced — compared to current price %131.3 undervalued.
Current price: 4.67
Debt Cycle Phase
Geç Genişleme
Debt cycle phase: Geç Genişleme
Piotroski F-Score
6/9
Moderate Piotroski (6/9). Some balance sheet criteria met, some missing. Note: Operating cash flow data missing (C3, C4)
Neutral
Graham Intrinsic Value
A$2.3
Graham intrinsic value: A$2.3. Pahalı
Expensive
⚖️ Sector Comparison
P/E Ratio
23.9x
vs 13.5x
Sector mediannın %78 above — expensive
P/B Ratio
3.74x
vs 2.25x
Compared to sector %66 more expensive (by book value)
EV/EBITDA
8.0x
vs 6.2x
Compared to sector %29 higher EV/EBITDA
ROIC vs WACC
%10.0
vs %7.9 WACC
ROIC 2.0 baz puan exceeds cost of capital
Net Profit Margin (TTM)
%9.6
vs %37.8 EBITDA margin
TTM net profit margin %9.6
Charts
Indicators
BB deviation
?
RSI thresholds
?
TLS — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.